Aneurysmal subarachnoid hemorrhage
Conditions
Interventions
multiple lumbar puncture group:multiple lumbar puncture
lumbar cistern puncture and drainage group:lumbar cistern puncture and drainage
Sponsors
Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Aged > 18 years; (2) Patients with a CT diagnosis of SAH and a diagnosis of aSAH confirmed by CT angiography or digital subtraction angiography; (3) Patients who are hospitalized within 72 hours after the onset of the disease and undergo surgical treatment of aneurysm (craniotomy clamping or interventional embolization); (4) Patients with a Fisher classification of >= 2; (5) Those with a pre-onset mRS score of 0 (indicating no symptoms) or 1 (indicating mild symptoms, not affecting daily activities); (6) Patients or their legal representatives sign a written informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients who are suspicious of aSAH due to non-aneurysm causes, such as hemorrhagic tendency-related diseases, trauma, tumor, arteriovenous malformation, cavernous hemangioma, etc; (2) Patients with a previous history of central nervous system disease; (3) Patients with a combination of acute or chronic infectious diseases at the time of onset; (4) Patients with systemic diseases such as cardiac, hepatic, renal, hematologic, and autoimmune diseases, as well as neoplasms (5) Patients with a history of taking anticoagulant, antiplatelet, and pro-fibrinolytic medications within 1 month prior to admission; (6) Patients who are pregnant or whose life expectancy is shorter than the study period; (7) Patients requiring early extraventricular drainage due to acute hydrocephalus or intracranial hypertension; (8) Patients with poor compliance with any treatment or study; (9) Absolute contraindications for lumbar puncture or lumbar drain placement, such as brain herniation or infection at the puncture site; (10) Other conditions deemed by the investigator to be inappropriate for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of hydrocephalus; | — |
Secondary
| Measure | Time frame |
|---|---|
| mRS scoring;GOS prognostic scoring;Incidence of delayed cerebral ischemia;All-cause mortality rate;Rate of central nervous system infections;Incidence of epilepsy ;Decompressive craniectomy rate;Rebleeding rate;MoCA scoring;MMSE scoring;Length of stay;Improvement rate of first symptoms; | — |
Countries
China
Contacts
Public ContactMingchang Li
Renmin Hospital of Wuhan University
Outcome results
None listed